Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Mumbai Crime Branch Arrests Man In Fake Police Robbery Case Involving ₹2 Crore Cash Loot In Girgaum Area
Irregularities Detected In DBT Transfers Under Prime Minister’s Matru Vandana Yojana
Cough Syrup Scam: ED Probes Money Laundering Via Luxury Cars With ‘9777’ And ‘1111’ Number Series
BMC Appoints 46 Election Officers, Signalling Imminent Announcement Of Civic Polls
